Halozyme Therapeutics Inc.
HALO
Get informed when a big investor buys or sells
+ FollowCurrent Fair Value
83.6% upsideUndervalued by 83.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $7.89 Billion |
|---|---|
| Enterprise Value | $7.79 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $2.64 |
| Beta | 0.88 |
| Outstanding Shares | 118,144,000 |
Return
| Return on Equity | 158.83% |
|---|---|
| Return on Assets | 13.05% |
| Return on Invested Capital | 37.74% |
Valuation & Multiples
| P/E Ratio | 22.54 |
|---|---|
| PEG | 83.29 |
| Price to Sales | 5.82 |
| Price to Book Ratio | 69.82 |
| Enterprise Value to Revenue | 5.17 |
| Enterprise Value to EBIT | 8.94 |
| Enterprise Value to Net Income | 22 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.95 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.7799▲ 16.14% |
|---|---|
| Total Calls | 319,000▼ 9.73% |
| Total Puts | 248,800▲ 13.82% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 100.26%▼ 4.84% |
|---|---|
| Total Invested | $7.77B▼ 6.30% |
| Investors Holding | 648▲ 18.00% |
ESG Score
No data
About Halozyme Therapeutics Inc.
CEO: Helen Torley Relevant Senate Committees
This powerful committee controls taxation, trade, and entitlement spending, driving corporate valuations through tax policy and significantly impacting the healthcare sector through Medicare pricing and reimbursement policies for biological products.
This committee directly regulates the FDA, which is essential for drug approval and market access for Halozyme's biological products, and influences NIH funding for research that can impact the biotech sector.
This committee's oversight of antitrust laws and intellectual property is critical for Halozyme, directly impacting M&A opportunities and the protection of its proprietary enzyme technology and drug formulations.